Hepatocellular Carcinoma Gene Expression: The New Era, Where It goes?

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.

Baumert TF, Juhling F, Ono A, et al. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017; 15: 52.

Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis 2017;38(1): 2–11.

Adeniji N, Dhanasekaran R. Genomic Landscape of HCC. Curr Hepatology Rep 2020; 19: 448–61.

Tobari M, Hashimoto E, Taniai M, et al. The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol 2020; 35: 862–9.

Menahem B, Lubrano J, Duvoux C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: an attempt to perform an ideal meta-analysis. Liver Transpl 2017; 23: 836–44.

Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020; 5: 87.

Xu W, Liu K, Chen M, et al. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Ther Adv Med Oncol 2019; 11: 1758835919862692.

Takeda H, Takai A, Eso Y, et al. Genetic Landscape of Multistep Hepatocarcinogenesis. Cancers 2022; 14: 568.

Brunner SF, Roberts ND, Wylie LA, et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 2019; 574: 538–42.

Zhang B-L, Ji X, Yu L-X, et al. Somatic mutation profiling of liver and biliary cancer by targeted next-generation sequencing. Oncol Lett 2018; 16: 6003–12.

Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 2016; 37: 865–76.2016.

Villanueva A, and Hoshida Y. Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol 2011; 55: 724–5.

Zhu Z-Z, Bao L-L, Zhao K, et al. Copy number aberrations of multiple genes identified as prognostic markers for extrahepatic metastasis-free survival of patients with hepatocellular carcinoma. Curr Med Sci 2019; 39: 759–65. 2019.

Long J, Wang A, Bai Y, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine 2019; 42: 363–74.

Huang C-Y, Hsieh F-S, Wang C-Y, et al. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer 2018; 102: 10–22.

a Liu Y, Yan J, and Wang F. Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients. Oncol Lett 2018; 16: 5733–8.

Li L, Rao X, et al. Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. Oncol Lett. 2020; 19(4): 2739–48.

Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51: 202–6.

Torrecilla S, Sia D, Harrington AN, et al. Trunk mutational events present minimal intra- and intertumoral heterogeneity in hepatocellular carcinoma. J Hepatol 2017; 67: 1222–31.

Donaires FS, Scatena NF, Alves-Paiva RM, et al. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma. PLoS One 2017; 12: e0183287.

Cheng Y, Huang M, Xie W, et al. Chromosome 8q24 amplification predicts prognosis for patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2019; 37: e15654.

Li X, Xu W, Kang W, et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics 2018; 8: 1740–51.

Trung NT, Hoan NX, Trung PQ, et al. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma. Sci Rep 2020; 10: 8181.

Jiao J, Watt GP, Stevenson HL, et al. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors. Hepatology Communications 2018; 2: 718–31.

Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. Journal of Hepatocellular Carcinoma 2018; 5: 61–73.

Waisberg J. (2015); Wnt−/−β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol 2015; 7: 2631.

Li P, Cao Y, Li Y, et al. Expression of Wnt-5a and β-catenin in primary hepatocellular carcinoma. Int J Clin Exp Pathol 2014; 7: 3190–5.

Ataide EC, Perales SR, Silva MG, et al. Immunoexpression of heat shock protein 70, glypican 3, glutamine synthetase, and beta-catenin in hepatocellular carcinoma after liver transplantation: association between positive glypican 3 and beta-catenin with the presence of larger nodules. Transplant Proc 2017; 49: 858–62.

Yuan K, Xie K, Lan T, et al. TXNDC12 promotes EMT and metastasis of hepatocellular carcinoma cells via activation of β-catenin. Cell Death Differ 2020; 27: 1355–68.

Cui Y, Wu X, Lin C, et al. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/β-catenin/CBP signaling pathway. Oncogene 2019; 38: 5516–29.

Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification. J Hepatol 2017; 67: 727–38.

Doycheva I, and Thuluvath PJ. Systemic therapy for advanced hepatocellular carcinoma: an update of a rapidly evolving field. J Clin Exp Hepatol 2019; 9: 588–96.

Zheng A, Chevalier N, Calderoni M, et al. CRISPR/Cas9 genome-wide screening identifies KEAP1 as sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma. Oncotarget 2019; 10: 7058–70.

Hechtman JF, Abou-Alfa GK, Stadler ZK, et al. Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. Hum Pathol 2019; 83: 1–6.

Xiong S, Wang R, Chen Q, et al. Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling. Am J Cancer Res 2018; 8: 302–16.

Yang L, Zhang X-Y, Li K, et al. Protopanaxadiol inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by targeting the STAT3 pathway. Cell Death Dis 2019; 10: 630.

Yoo C, Kang J, Kim K-P, et al. Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma. J Clin Oncol 2018; 36: 4078.

Zhou C, Zhang W, Chen W, et al. Integrated analysis of copy number variations and gene expression profiling in hepatocellular carcinoma. Sci Rep 2017; 7: 10570.

Yu M-C, Lee C-W, Lee Y-S, et al. Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data. World J Gastroenterol 2017; 23: 7818–29.

Kent LN, Bae S, Tsai S-Y, et al. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest 2017; 127: 830–42.

Yu X, Huang J, Wu S, et al. Copy number variations of MMP-9 are prognostic biomarkers for hepatocellular carcinoma. Transl Cancer Res 2020; 9: 698–706.

Zhou S-L, Zhou Z-J, Hu Z-Q, et al. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. J Hepatol 2019; 71: 1152–63.

Zhang B, Deng C, Wang L, et al. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through a β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway. Mol Carcinog 2018; 57: 201–15.

Kaibori M, Sakai K, Ishizaki M, et al. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget 2016; 7: 49091–8.

Gentilini D, Scala S, Gaudenzi G, et al. Epigenome-wide association study in hepatocellular carcinoma: identification of stochastic epigenetic mutations through an innovative statistical approach. Oncotarget 2017; 8: 41890–902.

Shen J, Wang S, Zhang Y-J, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012; 55: 1799–808.

Wu X, Yao X, Cao Q, et al. Clinicopathological and prognostic significance of CDH1 hypermethylation in hepatocellular carcinoma: a meta-analysis. Cancer Manag Res 2019; 11: 857–64.

Cheng J, Wei D, Ji Y, et al. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. Genome Med 2018; 10: 42.

Gailhouste L, Liew LC, Yasukawa K, et al. Differentiation therapy by epigenetic reconditioning exerts antitumor effects on liver cancer cells. Mol Ther 2018; 26: 1840–54.

Liu J, Liu Y, Meng L, et al. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 2017; 38: 899–907.

Jueliger S, Lyons J, Cannito S, et al. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Epigenetics 2016; 11: 709–20.

Xu X, Tao Y, Shan L, et al. The role of MicroRNAs in hepatocellular carcinoma. J Cancer 2018; 9: 3557–69.

van der Ree MH, van der Meer AJ, van Nuenen AC, et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment Pharmacol Ther 2016; 43: 102–13.

Lee J-S, Chu I-S, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667–76.

Segal E, Friedman N, Koller D, et al. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004; 36: 1090–8.

Li Y, Farmer RW, Yang Y, et al. Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistance. BMC Cancer 2016; 16: 228.

Mani SKK, Zhang H, Diab A, et al. EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. J Hepatol 2016; 65: 888–9.

Ye C, Zhang X, Chen X, et al. Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4. Cell Oncol 2020; 43: 279–95.

Zhang B-H, Yang J, Jiang L, et al. Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma. Genomics 2020; 112: 2763–71.

Li N, Zhao L, Guo C, et al. Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma. Cancer Manag Res 2019; 11: 7473–84.

Chan L-K, and Ng IO-L. Proteomic profiling in liver cancer: another new page. Transl Gastroenterol Hepatol 2019; 4: 47.

Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of earlystage hepatocellular carcinoma. Nature 2019; 567: 257–61.

Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 2019; 179(2): 561–77.

He Y, Luo Y, Zhang D, et al. PGK1- mediated cancer progression and drug resistance. Am J Cancer Res 2019; 9: 2280–302.

Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet 2016; 48: 500–9.

Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet 2015; 47: 505–11.

Li S-P, Xu H-X, Yu Y, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 2016; 7: 42431–46.

Fujisaka Y, Iwata T, Tamai K, Nakamura M, et al. Long non-coding RNA HOTAIR up-regulates chemokine (C-C motif) ligand 2 and promotes proliferation of macrophages and myeloid-derived suppressor cells in hepatocellular carcinoma cell lines. Oncol Lett. 2017;15(1): 509–14.

Yang Y, Zhang J, Wu T, et al. Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1. Life Sci 2019; 216: 200–6.

Lin DC, Mayakonda A, Dinh HQ, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res 2017; 77: 2255–65.

Zhai W, Lim TK, Zhang T, et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun 2017; 8: 4565.